1. Home
  2. TBPH vs CRTO Comparison

TBPH vs CRTO Comparison

Compare TBPH & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.08

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$18.30

Market Cap

806.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
CRTO
Founded
2013
2005
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
824.9M
806.9M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
TBPH
CRTO
Price
$16.08
$18.30
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$18.40
$34.00
AVG Volume (30 Days)
289.3K
367.1K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
279.13
38.95
EPS
N/A
0.15
Revenue
$15,386,000.00
$2,296,692,000.00
Revenue This Year
$8.46
N/A
Revenue Next Year
N/A
$5.54
P/E Ratio
N/A
$122.23
Revenue Growth
N/A
27.65
52 Week Low
$9.98
$15.58
52 Week High
$21.03
$27.32

Technical Indicators

Market Signals
Indicator
TBPH
CRTO
Relative Strength Index (RSI) 40.51 56.18
Support Level $13.41 $18.04
Resistance Level $17.21 $19.98
Average True Range (ATR) 0.34 0.60
MACD -0.06 0.23
Stochastic Oscillator 4.84 82.82

Price Performance

Historical Comparison
TBPH
CRTO

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.

Share on Social Networks: